Recalls & Alerts Published by NAFDAC

The National Agency for Food and Drug Administration and Control has been informed that the General Council Medical Colleges of Spain in the January/February 2018 edition of its Journal of Tropical Medicine alerted that a batch of fake Penicillin-V(Phenoxymethyl Penicillin)is in circulation in the South-West region of Cameroun.

Penicillin –V is indicated for tonsillitis, otitis media, oral infection, group A streptococcal infection and rheumatic fever.

The details of the fake Penicillin V in circulation are as follows:

Product Name Penicillin- V Tablets
Active Pharmaceutical Ingredient Phenoxymethyl Penicillin
Batch Number 190
Manufacturing Date April 2015
Expiry Date October 2019
Manufacturer stated on package label Oxford Pharma Co. Ltd, Belgium

NAFDAC implores all pharmaceuticalimporters, distributors, wholesalers, retailers, healthcare providers and consumersto be vigilant and notify the nearest NAFDAC office of any information concerning the distribution, sale and use of the fake Penicillin-V tablet.

Anybody in possession of the fake Penicillin –V tablets should submit it to the nearest NAFDAC office.

Report adverse events related to the use of the fake product to NAFDAC PRASCOR (20543 Toll free from all networks) or via This email address is being protected from spambots. You need JavaScript enabled to view it. .

NAFDAC…………….Safeguarding the health of the Nation

Signed Management

Public Alert no. 05/2018 – Contaminated Meat Products From South Africa.

CONTAMINATED PROCESSED MEAT PRODUCTS PRODUCED BY ENTERPRISE CORPORATION AND RAINBOW CHICKEN LIMITED, SOUTH AFRICA

The National Agency for Food and Drug Administration and Control (NAFDAC) hereby alerts the public on the recent outbreak of Listeriosis in South Africa. Listeriosis is a serious disease caused by the bacterium, Listerium monocytogenes.

As at 2nd March, 2018, nine hundred and forty eight (948) laboratory confirmed cases of Listeriosis were recorded with one hundred and eighty (180) deaths.

Laboratory investigation established that the source of the outbreak was confirmed as ready-to-eat processed meat products – polony, followed by Vienna sausages and other “cold meat” manufactured by Enterprise Corporation Food Facility and Rainbow Chicken Limited in Polokwane, South Africa.

The South African Minister of Health issued a Press Statement to confirm the source of the outbreak as processed meat products manufactured by Enterprise Corporation and Rainbow Chicken Limited. In addition, the Consumer Protection Act of South African issued a safety recall notices on 4th March, 2018 to manufacturers of these products. The safety recall includes the manufacturer’s entire distribution network, both domestic and international.

NAFDAC has strengthened surveillance to prevent importation of contaminated processed meat products produced by Enterprise Corporation and Rainbow Chicken Limited, South Africa. The Agency has also strengthened surveillance on wholesale and retail outlets to seize and sanction any organization in possession of meat products produced by these companies.

All importers are warned to desist from importing processed meat products produced by Enterprise Corporation and Rainbow Chicken Limited, South Africa.

Distributors, wholesalers and retailers in possession of meat products produced by these companies are to submit them to the nearest NAFDAC office.

Anybody with information on distribution and sale of these unwholesome meat products should contact the nearest NAFDAC office, NAFDAC PRASCOR (20543 TOLL FREE from all networks) or via This email address is being protected from spambots. You need JavaScript enabled to view it. .

NAFDAC... Safeguarding the Health of the Nation.

Signed Management.

Dear Healthcare provider,                               

The National Agency for Food and Drug Administration and Control (NAFDAC) has been informed by united states food and drug administration (FDA) that Anaphylaxis, anaphylactic shock and other serious hypersensitivity reactions have been reported in the post marketing setting, some requiring hospitalization. These reactions have occurred during or soon after the infusion of Varubi (rolapitant) injectable emulsion. Symptoms of anaphylaxis may include wheezing or difficulty in breathing, swelling of the face or throat, hives or flushing, itching,abdominal cramping or vomiting, back pain or chest pain, hypotension or shock.

Varubi (rolapitant) injectable emulsion is approved to prevent delayed phase chemotherapy-induced nausea and vomiting (emesis). Varubi is approved in adult in combination with other drugs (antiemetic) that prevent nausea and vomiting associated with initial and repeat courses of vomit-inducing cancer chemotherapy.

Recommended Action

  • Health care professionals must be vigilant for signs of hypersensitivity or anaphylaxis in all patients receiving Varubi (rolapitant) injectable emulsion, both during and following its administration.
  • It is advised that health care professionals consult with patients to determine if they are hypersensitive to any component of the product including soy beans.
  • Patients with known allergies to legumes or other related allergens should be monitored closely.
  • Patient with known hypersensitivity should not be administered Varubi (rolapitant) injectable emulsion.
  • Appropriate treatment should be available for immediate use in the event of an anaphylactic reaction during treatment with Varubi (rolapitant) injectable emulsion.
  • If anaphylaxis or any other serious hypersensitivity /infusion reaction occurs, appropriate medical management should be initiated and Varubi should be permanently discontinued.
  • Healthcare providers and patients are encouraged to report adverse reactions associated with the use of these products to the nearest NAFDAC office, NAFDAC PRASCOR 920543 TOLL FREE from all networks) or via This email address is being protected from spambots. You need JavaScript enabled to view it.

NAFDAC… Safeguarding the health of the Nation

Signed Management

  •  Start 
  •  Prev 
  •  1 
  •  2 
  •  3 
  •  4 
  •  5 
  •  6 
  •  7 
  •  8 
  •  9 
  •  Next 
  •  End 
Page 1 of 9

ONLINE PORTALS

napams

Contact Us from Mon - Friday: 08:00-16:00 GMT+1

Write Us:

NAFDAC Corporate Headquarters,

Plot 2032, Olusegun, Obasanjo Way,

Zone 7, Wuse, Abuja, Nigeria

 

Lagos Operation Office:

Plot 1, Industrial Estate, Lagos- Oshodi Apapa Express Way, Isolo, Lagos, Nigeria

 

 

 

 

 

 

For Enquiries:

Call: +234(0)-1-4609750

Email:nafdac@nafdac.gov.ng

 

 

 

 

 

 

 

 

 

 

 

For Complaints:

Call: +234(0)909-763-0506

         +234(0)909-763-0507

Email:reforms@nafdac.gov.ng

Or Send Us a Complaint

 

 

 

 

 

 

 

 

 

Contact Other NAFDAC Offices Nationwide